Orano Forges Ahead with Strategic Growth Despite Revenue Dip

PARIS – February 20, 2026 – French nuclear fuel cycle leader Orano has presented its 2025 annual results, showing a notable decrease in reported revenue and adjusted net income. While the headline figures might suggest a slowdown, a closer look reveals a company with robust underlying performance, a significantly strengthened financial position, and a clear, ambitious strategy for future growth. The year-over-year comparison was heavily skewed by an exceptionally strong 2024, which was boosted by nearly €1 billion in one-off contracts.

Despite the challenging comparison, the company's leadership expressed confidence in its trajectory. "The group closed out the year 2025 with strong industrial performance from its plants and mining platforms, and successful management of its major development projects," said Nicolas Maes, Chief Executive Officer of Orano. "With a net debt at its lowest level, Orano now has a solid financial structure to support the ambitious development plan for all its activities."

Deconstructing the Financials: A Tale of Two Years

Orano's revenue for 2025 stood at €5.14 billion, a 12.5% decrease from the €5.87 billion reported in 2024. Similarly, adjusted net income attributable to owners of the parent fell to a loss of €25 million from a profit of €597 million in the prior year. However, this decline is almost entirely attributable to the high comparable base set in 2024, which included the exceptional contribution of contracts with Japanese utilities in the Back End segment.

Those 2024 agreements, involving the recycling of used nuclear fuel and the packaging of residual waste from Japanese reactors, provided a substantial, non-recurring revenue surge. When this one-off effect is excluded, Orano’s underlying business shows healthy momentum, with higher sales volumes in Mining and increased production in the Back End segment.

More telling indicators of the company's health are its cash flow and debt levels. Net cash flow from company operations rose to a positive €476 million, a significant improvement from €354 million in 2024. This was supported by strong operating performance and a strategic cash injection from Sanofi's acquisition of a stake in Orano Med Theranostics. Furthermore, the group substantially reduced its net debt, which fell to €0.44 billion from €0.78 billion at the end of 2024, marking a new low and underscoring its solid financial footing.

Securing the West's Nuclear Future: A Major US Investment

A cornerstone of Orano’s forward-looking strategy is its massive investment in the United States. In early January 2026, the company announced it was selected by the U.S. Department of Energy (DOE) to receive $900 million in financing for its project to build a new enriched uranium production facility at the Oak Ridge site in Tennessee.

This project, dubbed IKE, is estimated to cost nearly $5 billion and represents a critical step in re-shoring a secure nuclear fuel supply chain for the United States. The facility is designed to provide American nuclear reactor operators with a reliable source of enriched uranium, a move of immense strategic importance as U.S. regulations are set to prohibit the import of Russian uranium starting in 2028. By stepping in to fill this impending supply gap, Orano is positioning itself as an indispensable partner in ensuring Western energy security and sovereignty.

Diversifying Supply and Expanding Global Partnerships

Beyond the landmark U.S. project, Orano has been actively shoring up its global supply chain and forging new alliances to drive innovation. The company has successfully diversified its uranium mining portfolio to mitigate geopolitical risks and secure long-term resources. An arbitral tribunal decision in September 2025 ruled in Orano's favor in its dispute with Niger over the SOMAÏR uranium mine, protecting its assets.

Simultaneously, Orano strengthened its partnership in Uzbekistan within the Nurlikum Mining joint venture. This move paves the way for the industrial development of the 'South Djengeldi' uranium deposit, which is projected to produce an average of 500 metric tons of uranium per year, further diversifying the company's sources of raw material.

At the World Nuclear Exhibition in late 2025, Orano unveiled a series of strategic partnerships aimed at advancing nuclear technology. These include agreements to support its 'Aval du Futur' recycling facility renewal program, a partnership with Sintermat for next-generation nuclear packaging, and collaborations with Calogena and ULC-Energy to develop Small Modular Reactors (SMRs). These alliances demonstrate Orano's commitment to innovation across the entire nuclear value chain, from fuel production to advanced reactor technologies.

Investing Across the Fuel Cycle: From Medicine to Recycling

Orano’s ambitious agenda is backed by significant capital investment. Net Capex rose by 29.5% in 2025 to €1.27 billion, funding key projects like the capacity extension of the Georges Besse II enrichment plant and the ramp-up of the 'Aval du Futur' program, which aims to modernize its treatment-recycling facilities.

This strategy of investment extends beyond the traditional energy sector. The sale of a stake in its subsidiary Orano Med Theranostics to pharmaceutical giant Sanofi not only bolstered the company's cash position but also validated its venture into the promising field of nuclear medicine, which uses radioactive isotopes to target and destroy cancer cells.

Looking ahead, Orano has set a confident outlook for 2026, with revenue projected to remain above €5 billion and a healthy EBITDA-to-revenue rate between 23% and 25%. The company also introduced a new medium-term financial target, aiming for a financial leverage ratio of 1.5x or less by the end of 2028. This shift from a focus on deleveraging to a controlled leverage target signals that Orano is confidently entering a new phase of strategic investment and development, poised to capitalize on the growing global interest in nuclear power.